Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	32.46B
Revenue (ttm)	12.60B
Net Income (ttm)	2.24B
Shares Out	n/a
EPS (ttm)	2.46
PE Ratio	14.49
Forward PE	13.76
Dividend	1.48 (5.07%)
Ex-Dividend Date	Jul 8, 2024

Volume	1,134,130
Average Volume	1,372,919
Open	29.25
Previous Close	29.25
Day's Range	28.90 - 29.75
52-Week Range	23.10 - 34.00
Beta	0.34
RSI	65.09
Earnings Date	Aug 20, 2025

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precoci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY